Skip to content

European Journal of Clinical Pharmacology

ISSN 0031-6970, 1432-1041

9 papers in the library · 371 citations · publishing 2003-2026

Papers

Sort Most recent Most cited

Correction to: A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals.

European Journal of Clinical Pharmacology February 23, 2026 Claudia Pisanu, Shungo Imai, Masami Tsuchiya et al. correction

Correction to: European Journal of Clinical Pharmacology (2026) 82:13 h t t p s : / / d o i . o r g / 1 0 . 1 0 0 7 / s 0 0 2 2 8 -0 2 5 -0 3 9 5 4 -z At page 13, the correct version of " 60 vs. 3 days, p < 0.001, Table 3" is "60 vs. 2 days, p < 0.001, Table 3).The original article can be found online at h t t p s : / / d o i . o r g / 1 0 . 1 0 0 7 / s 0 0 2 2 8 -0 2 5 -0 3 9 5 4 -z

A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals

European Journal of Clinical Pharmacology December 22, 2025 Claudia Pisanu, Shungo Imai, Masami Tsuchiya et al. 3 citations

Our results increase knowledge on potential risks related to esketamine AEs and potential drug-drug interaction signals in a real-world setting.

DOI: 10.1007/s00228-025-03954-z (opens in new tab) Full text (opens in new tab) Pharmacovigilance Adverse effect Intensive care medicine Pharmacology +3

Post-market safety profile and suicide/self-injury risk signals of dextromethorphan/bupropion: a real-world pharmacovigilance study.

European Journal of Clinical Pharmacology July 1, 2025 Lingjing Yuan, Jianping He, Xiangyu Li 3 citations

Dextromethorphan/bupropion (D/B) is an innovative pharmacological treatment for major depressive disorder. Nevertheless, the current evidence regarding the safety profile of D/B is predominantly derived from clinical trials, thus hindering the timely updating of adverse event (AE) data for this medication. Therefore, this study conducted data mining and analysis of AE signals (especially for...

DOI: 10.1007/s00228-025-03841-7 (opens in new tab) Full text (opens in new tab) Data mining Dextromethorphan/bupropion Faers Pharmacovigilance +7

The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.

European Journal of Clinical Pharmacology March 2023 Ehsan Motaghi, Masoumeh Ghasemi-Pirbaluti, Mohsen Rashidi et al.

Previous studies have shown that tetrahydrocannabinol (THC), the main psychoactive component of cannabis, can impair cognitive abilities. There is also some evidence that cannabidiol (CBD), the most abundant non-intoxicating constituent of cannabis, can attenuate these effects. The purpose of this study was to investigate the effects of THC:CBD oromucosal spray (with equal parts THC and CBD) on...

Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses

European Journal of Clinical Pharmacology October 27, 2021 T. Lima, M. B. Visacri, P. M. Aguiar 38 citations

To summarize the evidence of efficacy and safety of the use of ketamine and esketamine for depression. A literature search was performed in Medline, the Cochrane Library, LILACS, and CRD until November 2020. We included systematic reviews with meta-analyses of randomized controlled trials on the use of ketamine and esketamine in adult patients with depression. Two authors independently...

No major role of norepinephrine transporter gene variations in the cardiostimulant effects of MDMA

European Journal of Clinical Pharmacology December 2, 2017 Patrick Vizeli, Henriette E. Meyer zu Schwabedissen, Matthias E. Liechti 15 citations

Methylenedioxymethamphetamine (MDMA, ecstasy) is used recreationally and frequently leads to sympathomimetic toxicity. MDMA produces cardiovascular and subjective stimulant effects that were shown to partially depend on the norepinephrine transporter (NET)-mediated release of norepinephrine and stimulation of α 1 -adrenergic receptors. Genetic variants, such as single-nucleotide polymorphisms...

Effects of oral Δ9-tetrahydrocannabinol on the cerebral processing of olfactory input in healthy non-addicted subjects.

European Journal of Clinical Pharmacology December 2017 Carmen Walter, Bruno G Oertel, Lisa Felden et al.

Considering the increasing acknowledgment of the human sense of smell as a significant component of the quality of life, olfactory drug effects gain potential clinical importance. A recent observation in a human experimental context indicated that Δ9-tetrahydrocannabinol (THC) impaired the subject's performance in olfactory tests. To further analyze the role of THC in human olfaction, the...

DOI: 10.1007/s00228-017-2331-2 (opens in new tab) Full text (opens in new tab) Cannabis Human experimental study Human olfaction Statistical parametric mapping +1

Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine.

European Journal of Clinical Pharmacology May 1, 2012 David M Wood, Susannah Davies, Malgorzata Puchnarewicz et al.

Long-term regular use of ketamine has been reported to be associated with severe symptomatic urinary tract problems. Methoxetamine, an arylcyclohexylamine derivative of ketamine, is marketed as a "bladder safe" derivative of ketamine, and no cases of acute toxicity following analytically confirmed methoxetamine use have been reported to date. We report here a case series of three individuals...

Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

European Journal of Clinical Pharmacology September 1, 2003 Mats Bergstr�m, A. Grahn�n, B. L�ngstr�m 312 citations

The realisation that new chemical entities under development as drug candidates fail in three of four cases in clinical trials, together with increased costs and increased demands of reducing preclinical animal experiments, have promoted concepts for improvement of early screening procedures in humans. Positron emission tomography (PET) is a non-invasive imaging technology, which makes it...

DOI: 10.1007/s00228-003-0643-x (opens in new tab) Positron emission tomography Drug development In vivo Nuclear medicine +4